Новости
хирургии

 Журнал включен
в систему цитирования Scopus
journal cover
android icon Приложение Android

2008 г. №3 Том 16

ОHКОЛОГИЯ

Н.Г.ЛУД, К.Н. УГЛЯHИЦА, Л.Н.ЛУД

СОВРЕМЕHHЫЕ ПРИHЦИПЫ HЕОАДЪЮВАHТHОГО ЛЕЧЕHИЯ БОЛЬHЫХ РАКОМ МОЛОЧHОЙ ЖЕЛЕЗЫ

УО «Витебский государственный медицинский университет»,
УО «Гродненский государственный медицинский университет»,
Республика Беларусь

Лечение больных раком молочной железы зависит от стадии заболевания, возраста пациентки, морфологического строения опухоли и других факторов прогноза. Для уменьшения размеров опухоли перед хирургическим лечением при раке молочной железы применяют различные методы воздействия: лучевую, химио- и эндокринотерапию. В статье приводятся литературные сведения о неоадъювантной химиотерапии и эндокринной терапии больных раком молочной железы.

Ключевые слова: рак молочной железы, предоперационная химиотерапия и эндокринная терапия, неоадъювантное лечение, ингибиторы ароматазы, тамоксифен.
с. 80 – 91 оригинального издания
Список литературы
  1. Алгоритмы диагностики и лечения злокачественных новообразований / под ред. И. В. Залуцкого, Э. А. Жаврида. – Минск, 2007. – 512 с.
  2. Моисеенко, В. М. Современное лекарственное лечение местно–распространенного и метастатического рака молочной железы / В. М. Моисеенко, В. Ф. Семиглазов, С. А. Тюляндин. – СПб.: Грифон, 1997. – 254 с.
  3. Огнерубов, Н. А. Неоадъювантная химиолучевая терапия в комплексном лечении местнораспространенного рака молочной железы / Н. А. Огнерубов, В. П. Летягин, И. В. Поддубная. – Воронеж, 1993. – С. 72.
  4. II фаза клинических испытаний неоадъювантной эндокринотерапии в сравнении с химиотерапией у больных раком молочной железы / В. Ф. Семиглазов [и др.] // Вопросы онкологии. – 2007. – Т. 53, № 4. – С. 400-408.
  5. Семиглазов, В. Ф. Гормонотерапия рака молочной железы / В. Ф. Семиглазов, К. Ш. Нургазиев, А.С. Арзуманов // Опухоли молочной железы (лечение и профилактика). – Алматы: Полиграф сервис, 2001. – С. 226-232.
  6. Семиглазов, В. Ф. Неинвазивные и инвазивные опухоли молочной железы / В. Ф. Семиглазов, В.В. Семиглазов, А. Е. Клетцель. – М.: Боргесе, 2006. – 349 с.
  7. Тюляндин, С. А. Значение предоперационной химиотерапии у больных раком молочной железы / С. А. Тюляндин // Материалы IV ежегодной Российской онкологической конф., Москва, 21 – 23 ноябр., 2000 г. – С. 43-45.
  8. Сенсибилизация клеток рака молочной железы MCF–7 к апоптотическому действию эстрадиола / А. М. Щербакова [и др.] // Бюл. Экспер. Биол. – 2006. – № 141(3). – С. 334-337.
  9. Neoadjuvant endocrine therapy in breast cancer / С. Abrial [et al.] // Breast. – 2006. – Vol. 15. – P. 9-19.
  10. Estrogen and Resveratrol Regulate Rac and Cdc42 Signaling to the Actin Cytoskeleton of Metastatic Breast Cancer Cells / N. G. Azios [et al.] // Neoplasia. – 2007. – Vol. 9. – N 2. – P. 147-158.
  11. Sequential pre- operative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B–27 / H. D. Bear [et al.] // J. Clin. Oncol. – 2006. – Vol. 24. – P. 2019-2027.
  12. Beresford, M. J. Neoadjuvant endocrine therapy in breast cancer / M. J. Beresford, D. Ravichandran, A. Makris // Cancer Treat. Rev. – 2007. – Vol. 33. – P. 48-57.
  13. Breast cancer biology, treatment, and survival in elderly women / V. Bernstein [et al.] // Proc. Amer. Soc. Clin. Oncol. – 2001. – Vol. 20, N 247a. – Abstr. 985.
  14. Better characterization of estrogen receptor (ER) positive luminal subtypes using genomic grade / C. Sotiriou [et al.] // 6 General Breast Cancer Symposium Session, San Antonio, Dec. 8-11, 2005. – 2005, San Antonio, TX.
  15. Pharmacology of non-steroidal aromatase inhibitors / А. Bhatnagar [et al.] // Hormone–Dependent Cancer / eds. J. Pasqualini, B. Katzenellenbogen. – New York: Marcel Dekker, 1996. – P. 155-168.
  16. Bonadonna, G. From adjuvant to neo-adjuvant chemotherapy in high-risk breast cancer: the experience of the Milan Cancer Institute. Steiner Award Lecture 1992 / G. Bonadonna // Int. J. Cancer. – 1993. – Vol. 55. – P. 1-4.
  17. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute / G. Bonadonna [et al.] // J. Clin. Oncol. – 1998. – Vol. 16. – P. 93-100.
  18. Diet and body constitution in relation to subgroups of breast cancer defined by tumour grade, proliferation and key cell cycle regulators / S. E. Borgquist [et al.] // Breast Cancer Res. – 2007. – Vol. 9, N 1. – Abstr. – P. R11.
  19. Primary systemic therapy for operable breast cancer–10-year survival data after chemotherapy and hormone therapy / D. A. Cameron [et al.] // Brit. J. Cancer. – 1997. – Vol. 76. – P. 1099-1105.
  20. Castiglione-Gertsch, M. Adjuvant treatment of breast cancer: sequen duration of hormonal therapy / M. Castiglione-Gertsch // Ann. Oncol. – 2006. – Vol. 17. – Suppl. 10. – P. 51-53.
  21. Castiglione-Gertsh, M. Adjuvant endocrine therapies for postmenopausal women: standards and not / М. Castiglione-Gertsh // Breast. – 2005. – Vol. 14. – Suppl. 1. – Abstr. S24. – P. 9.
  22. Chemoendocrine therapy for premenopausal women with axillary lymph node–positive, steroid hormone receptor–positive breast cancer: results from INT 0101 (E51288) / N. E. Davidson [et al.] // J. Clin. Oncol. – 2005. – Vol. 23. – P. 5973-5982.
  23. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node–negative breast cancer / М. Colleoni [et al.] // J. Clin. Oncol. – 2001. – Vol. 19. – P. 4141-4149.
  24. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer / В. С. Coombes [et al.] // New Engl. J. Med. – 2004. – Vol. 350. – P. 1081-1092.
  25. Estrogen receptor б regulates expression of the breast cancer 1 associated ring domain 1 (BARD1) gene through intronic DNA sequence / A. L. Creekmore [et al.] // Mol. Cell. Endocrinol. – 2007. – Vol. 267, N 1-2. – P. 106-115.
  26. Linkage of Progestin and Epidermal Growth Factor Signaling: Phosphorylation of Progesterone Receptors Mediates Transcriptional Hypersensitivity and Increased Ligand-Independent Breast Cancer Cell Growth / A. R. Daniel [et al.] // Steroids. – 2007. – Vol. 72. – N 2. – P. 188-201.
  27. Dixon, J. Phase lib study of neoadjuvant exemestane (EXE) in locally advanced breast cancer / J. Dixon, I. Anderson, W. Miller // Proc. Amer. Soc. Clin. Oncol. – 2001. – Vol. 20. – Abstr. 1908.
  28. Dixon, J. M. Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies / J. M. Dixon, N. Bundred // Europ. J. Surg. Oncol. – 2006. – Vol. 32. – P. 123-125.
  29. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study / W. Eiermann [et al.] // Ann. Oncol. – 2001. – Vol. 12. – P. 1527-1532.
  30. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB–1- and/or ErbB–2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial / M. J. Ellis [et al.] // J. Clin. Oncol. – 2001. – Vol. 19. – P. 3808-3816.
  31. Effect of pre-operative chemotherapy on the outcome of women with operable breast cancer / В. Fisher [et al.] // J. Clin. Oncol. – 1998. – Vol. 16. – P. 2672-2685.
  32. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer / J. C. Gazet [et al.] // Europ. J. Surg. Oncol. – 1994. – Vol. 20. – P. 207-214.
  33. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy / L. Gianni [et al.] // Clin. Cancer Res. – 2005. – Vol. 11. – P. 8715-8721.
  34. First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease / L. Gianni [et al.] // Proc. Amer. Soc. Clin. Oncol. – 2002. – Vol. 21. – Abstr. 132.
  35. Exemestane as neoadjuvant treatment in patients >65 years with T>3 cm; preliminary results of a multicenter Spanish phase II trial / М. Gil [et al.] // Paper presented at: San Antonio Breast Cancer Symposium, 2002, San Antonio. – Abstr.
  36. A randomizet trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primare breast cancer / R .C. Goombes [et al.] // New Engl. J. Med. – 2004. – Vol. 350. – Р. 1081-1092.
  37. Kaufmann, M. Preoperative (neoadjuvant) systemic treatment of breast cancer / М. Kaufmann, G. Minckwitz, А. Rody // Breast. – 2005. – Vol. 14. – P. 576-581.
  38. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update / М. Kaufmann [et al.] // J. Clin. Oncol. – 2006. – Vol. 24. – P. 1940-1949.
  39. Phase II study to define safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancer-final results of the German Neoadjuvant Aromasin Initiative (GENARI) / U. Krainick [et al.] // Breast Cancer Res. Treat. – 2003. – Vol. 82. – Abstr. – P. 55.
  40. Lonning, P. E. Aromatase inhibitors and inactivators for breast cancer therapy / P. E. Lonning // Drug Aging. – 2002. – Vol. 19. – P. 277-298.
  41. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer / А. Makris [et al.] // Ann. Oncol. Nov. – 1998. – Vol. 9. – P. 1179-1184.
  42. Mauri, D. Neoadjuvant versus adjuvant systemic treatment for breast cancer: a meta-analysis / D. Mauri, N. Pavlidis, J. P. Loannidis // J. Natl. Cancer Inst. – 2005. – Vol. 97. – P. 188-194.
  43. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women / L. Mauriac [et al.] // Ann. Oncol. – 2002. – Vol. 13. – P. 293-298.
  44. Miller, W. R. Aromatase inhibitors and breast cancer / W. R. Miller // Minerva Endocrinol. – 2006. – Vol. 31. – P. 27-46.
  45. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up / J. F. Robertson [et al.] // Europ. J. Cancer. – 1992. – Vol. 28A. – P. 908-910.
  46. Santen, R. J. Endocrine-responsive cancer / R. J. Santen // Williams’ textbook of endocrinology / eds. P. R. Larsen [et al.]. – Philadelphia: W.B. Saunders Сотр., 2003. – P. 1797-1833.
  47. Santen, R. J. Estrogen synthesis inhibitors for breast cancer: an introductory overview / R. J. Santen // Endocrine-Related Cancer. – l996. – Vol. 3. – P. 1-8.
  48. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial / S. M. Scholl [et al.] // Europ. J. Cancer. – 1994. – Vol. 30A. – P. 645-652.
  49. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast / G. F. Schwartz [et al.] // Cancer (Philad.). – 1994. – Vol. 73. – P. 362-369.
  50. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1–2, T3NO–1, T4NOMO) / V. Semiglazov [et al.] // J. Clin. Oncol. – 2005. – Vol. 23. – Abstr. – P. 530.
  51. Neoadjuvant endocrine therapy of postmaeno-pausal breast cancer patients / V. Semiglazov [et al.] // Proc. Fourteenth International Congress on Anti-cancer Treatment. – Paris, 2003. – P. 174.
  52. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage llb–llla breast cancer / V. F. Semiglazov [et al.] // Ann. Oncol. – 1994. – Vol. 5. – P. 591-595.
  53. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in post-menopausal women with ER-positive breast cancer / V. F. Semiglazov [et al.] // J. Clin. Oncol. – 2004. – Vol. 22. – P. 519.
  54. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel / I. C. Smith [et al.] // J. Clin. Oncol. – 2002. – Vol. 20. – P. 1456-1466.
  55. Phase II study of neo-adjuvant exemestane in postmenopausal patients with operable breast cancer / М. Tubiana-Hulin [et al.] // Breast Cancer Res. Treat. – 2003. – Vol. 82. – Abstr. – P. 106.
  56. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004 / Е. Р. Winer [et al.] // J. Clin. Oncol. – 2005. – Vol. 23. – P. 619-629.
  57. Exemestane combined with epirubicin, Q1w X (8-12), as preoperative chemoendocrine treatment for patients with primary breast cancer: a phase I study / С. Wolf [et al.] // Proc. Amer. Soc. Clin. Oncol. – 2001. – Vol. 20. – Abstr. 1819.
  58. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 / N. Wolmark [et al.] // Journal of the National Cancer Institute Monogr. – 2001. – Vol. 30. – P. 96-102.
Адрес для корреспонденции:
210023, Республика Беларусь, г. Витебск, пр-т. Фрунзе, 27
e-mail: admin@vgmu.vitebsk.by
230009,Республика Беларусь, г.Гродно, ул.Горького, 80
e-mail: mailbox@grsmu.by
Контакты | ©Витебский государственный медицинский университет, 2007-2023